Antidiabetic Activity of Bacoside-A in Nicotinamide-Streptozotocin Induced Type 2 Diabetes in Rats

Background and Objective: Diabetes mellitus (DM) and its related complications such as neurotoxicity and cardiotoxicity are serious health problems. The DM and its complications altered the gut microbiota due to the expansion of the disease. Bacoside-A exhibited a preventive effect against inflammation and oxidative stress. In this experimental study, we try to explore the neuroprotective and cardioprotective effect of Bacoside-A against streptozotocin (STZ) induced renal and cardiac disease via alteration of gut microbiota. Materials and Methods: Single intraperitoneal injection of STZ (60 mg kg(-1)) was used to induce diabetes. The rats were divided into different groups and received various doses of Bacoside-A and rosiglitazone (1 mg kg(-1)). Blood glucose level, body weight were estimated. Hepatic, antioxidant, and inflammatory cytokines were estimated. Results: Bacoside-A treatment significantly (p<0.001) suppressed the glucose level, and enhanced the body weight. Bacoside-A treatment significantly (p<0.001) suppressed oxidative stress by increasing the level of SOD, GPx, CAT and GSH and suppressing the level of MDA. Bacoside-A treatment significantly (p<0.001) suppressed the inflammatory cytokines such as TNF-alpha, IL-1 beta and IL-6. Conclusion: Bacoside-A exhibited the renal and cardioprotective effect against STZ-induced DM rats via reduction of oxidative stress and inflammatory reaction.